Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesAllergy/Clinical Immunologyeocco Xolair (omalizumab) Coverage Prior Auth | Op…
    Ask Trek AI about this page
    CurrenteoccoPolicy M-P0146

    Xolair (omalizumab) (Subcutaneous) — Concomitant therapy restrictions and dosing guidance

    Customize your policy alerts

    Sign up for eocco Policy M-P0146 alerts

    Get alerted when Policy M-P0146 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Lists agents that are contraindicated for concurrent use with subcutaneous omalizumab (Xolair) under this payer policy; applicable to providers requesting coverage or administering Xolair.

    Policy Summary
    Payereocco
    PolicyXolair (omalizumab) (Subcutaneous) — Concomitant therapy restrictions and dosing guidance
    Policy CodePolicy M-P0146
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionPrior authorization reviewers must confirm the patient is not concurrently receiving any agent listed as contraindicated for concomitant therapy and document pre-treatment serum total IgE and body weight to select dosing.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ~60named agents listed as contraindicated concomitant therapies in this extract
    ~30unique agents listed as 'Not to be used Concomitantly' in this section
    J2357HCPCS code for omalizumab
    4

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    NDC presentations listed
    4Indications with dosing guidance

    Coverage Criteria for Omalizumab (Xolair)

    Initial dosing and medical necessity

    Dosing and coverage are based on indication and require meeting the following dosing-determination rules.

    Indication-specific dosing: Select one of the approved indications: moderate-to-severe persistent asthma; chronic spontaneous urticaria; chronic rhinosinusitis with nasal polyps; or IgE-mediated food allergy.

    From chunk 76

    Baseline testing: Obtain pre-treatment serum total IgE (IU/mL) measured before starting therapy and document body weight (kg) to determine dose and dosing frequency per the policy tables.IgE and weight per tables

    From chunks 76-77

    Dose selection: Select dose (mg) and dosing interval (every 2 or 4 weeks) using the policy's IgE-by-weight dosing tables. Examples in the tables include doses from 75 mg up to 600 mg depending on indication, pre-treatment total IgE, and body weight.refer to tables

    From chunks 77-83

    Dosing-based medical necessity

    Dosing and medical necessity reference weight- and indication-specific tables; coverage requires dosing within specified table ranges and avoidance of table entries labeled 'Do Not Dose'.

    General dosing requirement: Administer omalizumab at doses and intervals that match the policy's weight- and IgE-specific tables for the indicated condition (for example, IgE-mediated food allergy and other listed indications). Do not administer when the applicable table entry is labeled 'Do Not Dose'.weight- and IgE-dependent per tables

    Extensive tables in document define mg per dosing interval; certain entries indicate 'Do Not Dose' for specific high-weight/IgE combinations.

    The policy lists numerous biologic and targeted therapies that are contraindicated for concomitant use with subcutaneous omalizumab (Xolair). Examples named in the policy include: Exdensur (depemokimab-ulaa), Fasenra (benralizumab), and multiple adalimumab products such as Hadlima (adalimumab-bwwd), Hulio (adalimumab-fkjp), and Humira (adalimumab).

    Additional agents explicitly listed as contraindicated to use concomitantly with omalizumab include: Leqselvi (deuruxolitinib), Litfulo (ritlecitinib), Nemluvio (nemolizumab‑ilto), Nucala (mepolizumab), Olumiant (baricitinib), and the anti‑TNF/anti‑IL agents such as Inflectra (infliximab‑dyyb) / infliximab and Kevzara (sarilumab).

    The policy further enumerates other biologics and biosimilars not to be used concomitantly, including but not limited to: Opzelura (ruxolitinib), Orencia (abatacept), Otezla / Otezla XR (apremilast), multiple ustekinumab products (e.g., Stelara, Otulfi, Pyzchiva), and a broad list of monoclonal antibodies and JAK inhibitors such as Rituxan / rituximab, Ruxience (rituximab-pvvr), Tremfya (guselkumab), Taltz (ixekizumab), and others named in the section.

    Concurrent use of a broad group of biologic and targeted therapies is contraindicated; the policy explicitly calls out multiple classes and branded agents as examples, including anakinra (Kineret), mepolizumab (Nucala), baricitinib (Olumiant), various anti‑TNF and anti‑IL agents, and several branded biologics and biosimilars such as Kevzara (sarilumab) and Omvoh (mirikizumab-mrkz).

    Certain entries in the dosing tables are labeled Do Not Dose; these table entries represent explicit exclusions where omalizumab administration is not recommended for the specified body weight/IgE combinations.

    The dosing tables include high body weight and/or very elevated pre‑treatment serum total IgE combinations that are marked Do Not Dose, indicating dosing is not recommended for those specific weight/IgE bands and such combinations should not be used to determine eligible dosing.

    Billing and Coding

    Covered HCPCS CodesHCPCSCovered
    J2357Injection, omalizumab, 5 mg; 1 billable unit = 5 mg
    NDCsNDC
    50242-0214-xxXolair 75 mg single-dose prefilled syringe or autoinjector
    50242-0215-xxXolair 150 mg single-dose prefilled syringe or autoinjector
    50242-0040-xxXolair 150 mg single-dose vial powder for injection
    50242-0227-xxXolair 300 mg single-dose prefilled syringe or autoinjector
    Covered ICD-10 CodesICD-10Covered
    J33.0Polyp of nasal cavity
    J33.1Polypoid sinus degeneration
    J33.8Other polyp of sinus
    J33.9Nasal polyp, unspecified
    J45.40Moderate persistent asthma, uncomplicated
    J45.50Severe persistent asthma, uncomplicated
    L29.89Other pruritus
    L29.9Pruritus, unspecified
    L50.0Allergic urticaria
    L50.1Idiopathic urticaria
    1–10 of 21
    1/3
    inv-12: Pre-treatment serum total IgE — IgE ranges used in dosing tables
    IgE ranges shown in dosing tablesExamples include 30–100 IU/mL; >100–200 IU/mL; >200–300 IU/mL; >300–400 IU/mL (used to determine dose and dosing frequency)
    Lowest IgE band in table examples30–100 IU/mL (associated example doses: 150 mg or 300 mg depending on weight)
    Mid-range IgE bands>100–200 IU/mL and >200–300 IU/mL (associated with higher mg dosing in tables, up to 300 mg and above)
    Highest explicit IgE band referenced>300–400 IU/mL (table entries reference higher dosing ranges and cross-reference additional tables)
    inv-13: Body weight — weight bands used in dosing tables (examples shown)

    Provider Actions and Prior Authorization Requirements

    Prior Authorization

    PA reviewers require confirmation of no contraindicated concomitant agents

    Prior authorization reviewers will require confirmation that none of the agents listed as “Contraindicated as Concomitant Therapy” or “Agents NOT to be used Concomitantly” are being used concurrently with omalizumab.

    • Example listed agents include depemokimab-ulaa (Exdensur), benralizumab (Fasenra), various adalimumab products (Hadlima, Hulio, Humira, Hyrimoz), vedolizumab (Entyvio), canakinumab (Ilaris), mepolizumab (Nucala), baricitinib (Olumiant), ruxolitinib (Opzelura), rituximab products, ustekinumab products, and many others explicitly named in the policy.
    Prior Authorization

    PA must exclude use of agents on the prohibited list

    Prior authorization submissions must account for contraindicated concomitant therapies; requests that list or permit use of any agent on the policy’s prohibited list are not acceptable for approval.

    • The policy repeatedly states prior authorization must exclude use with agents listed as contraindicated for concomitant therapy.

    Background

    This section enumerates biologic, immunomodulatory, and related agents that are considered contraindicated for concomitant use with Xolair (omalizumab). The listed agents span multiple therapeutic classes (monoclonal antibodies, JAK inhibitors, PDE4 inhibitors, etc.) and include numerous branded products and biosimilars; avoidance of concurrent administration is required per the policy.

    Definitions and Key Terms

    inv-36: Contraindicated as Concomitant Therapy — definition/key value of agents explicitly listed as not to be administered with Xolair
    DefinitionAgents explicitly listed in the policy that should not be administered concomitantly with Xolair (omalizumab)
    Representative agents (non‑exhaustive)Examples include depemokimab-ulaa (Exdensur), benralizumab (Fasenra), multiple adalimumab products (Hadlima, Hulio, Humira, Hyrimoz)
    Action for providersDo not initiate or continue listed biologic/targeted agents at the same time as omalizumab without payer approval; documentation required for PA
    inv-37: Contraindicated as Concomitant Therapy — alternate chunk definition reiteration
    Restated definitionAgents listed in the policy section are not to be used at the same time as omalizumab; concomitant use is considered contraindicated by the payer
    Examples repeated in policy text

    Policy Revision History

    2026-07-01policy_reviewLatest

    Policy M-P0146 (Xolair®/omalizumab) last reviewed; NQTL checklist and dosing/contraindicated-concomitant therapy sections confirmed in the review.

    2026-07-01prior_authorization_considered

    Prior authorization considerations (NQTL factor checklist) documented, indicating PA is appropriate based on indication, safety/efficacy, and drug cost.

    Policy Summary
    Payereocco
    PolicyXolair (omalizumab) (Subcutaneous) — Concomitant therapy restrictions and dosing guidance
    Policy CodePolicy M-P0146
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionPrior authorization reviewers must confirm the patient is not concurrently receiving any agent listed as contraindicated for concomitant therapy and document pre-treatment serum total IgE and body weight to select dosing.
    SourceLink
    On This Page
    Coverage Criteria for Omalizumab (Xolair)Billing and CodingProvider Actions and Prior Authorization RequirementsBackgroundDefinitions and Key TermsPolicy Revision History
    Pediatric weight bands (example)
    10–12 kg; >12–15 kg; >15–20 kg; >20–25 kg (used in age 6 to <12 dosing tables)
    Adolescent/adult weight bands (examples)>30–40 kg; >40–50 kg; >50–60 kg; >60–70 kg; >70–80 kg; >80–90 kg; >90–125 kg; >125–150 kg
    Very large weight bands shownTables include progressive bands extending above 150 kg with larger numeric bands in extended tables
    inv-14: Weight-based dosing thresholds — examples of weight bands and corresponding dosing
    Dose determination methodDose (mg) and dosing frequency are determined by pre-treatment total IgE (IU/mL) and body weight (kg)
    Example: 30–100 IU/mL band dosingFor many weight bands within 30–100 IU/mL the table lists 150 mg (some weights 300 mg)
    Example: >100–200 IU/mL band dosingAssociated doses increase (examples include 150 mg, 300 mg, 450 mg, up to 600 mg depending on weight)
    High IgE/weight combinationsSome combinations reference 'See the following table' or indicate higher dosing bands (up to 600 mg every 2 or 4 weeks)
  1. Requests permitting listed agents are considered contraindicated and subject to denial.
  2. Prior Authorization

    PA must exclude concomitant use with listed agents

    When requesting prior authorization, exclude use of any agent named in the policy’s “Agents NOT to be used Concomitantly” list; PA determinations are made only if the request demonstrates the patient is not receiving those agents.

    • The policy instructs that prior authorization for omalizumab should account for and exclude use with the agents listed as contraindicated for concomitant therapy.
    • A long, explicit list of biologic and targeted agents is provided that must not be used concomitantly.
    Prior Authorization

    PA must state indication and IgE/weight‑based dosing

    Prior authorization must include the indication and the selected dosing determined by pre‑treatment total serum IgE and body weight, per the policy’s IgE‑by‑weight dosing tables.

    • Indication examples include moderate‑to‑severe persistent asthma, chronic spontaneous urticaria, chronic rhinosinusitis with nasal polyps, and IgE‑mediated food allergy.
    • Dose and dosing frequency are determined by serum total IgE measured before treatment and body weight; use the tables to select dose (e.g., 75–600 mg every 2 or 4 weeks as applicable).
    Prior Authorization

    Prior authorization expected/considered per NQTL factors

    Prior authorization is considered appropriate for omalizumab given indication, safety/efficacy considerations, and drug cost; use the NQTL checklist factors when applying PA.

    • Appendix A concludes indication, safety/efficacy, and cost are factors to “Consider for PA.”
    Documentation Required

    Verify absence of prohibited concomitant agents for PA

    Verify and document that the patient is not prescribed any agent on the policy’s prohibited list when submitting or renewing PA; do not request approval to co‑administer listed agents.

    • Requests that propose concomitant use of any agent listed as contraindicated are not acceptable and may be denied.
    • Providers must confirm absence of listed agents at the time of PA review.
    Prior Authorization

    State explicitly in PA that listed agents are not being used

    Include explicit statements in the PA that the member is not receiving any agents listed under “Agents NOT to be used Concomitantly”; PA that permits or lists such agents should be modified or will be considered contraindicated.

    • The policy repeats that concomitant use of named agents (e.g., mepolizumab, baricitinib, omalizumab-igec, mirikizumab, ruxolitinib, abatacept, apremilast, ustekinumab products) is contraindicated.
    • If concomitant therapy is documented, the request may be denied per the policy.
    Prior Authorization

    Do not request PA for concomitant administration of named agents

    Do not submit PA requests that seek approval to use omalizumab concurrently with any named biologic/targeted agents; PA determinations require exclusion of listed concomitant therapies.

    • The document provides extensive, repeated lists of agents that should not be co‑administered with Xolair; requests allowing those combinations are contraindicated.
    • Provider submissions must demonstrate the patient is not on those agents before approval.
    Prior Authorization

    Provide rationale if requesting an exception for concomitant use (may still be contraindicated)

    If a provider requests concomitant use despite the listing, include clinical rationale and supporting documentation; however, the policy indicates such combinations are contraindicated and may not be approved.

    • The policy notes a long list of contraindicated agents and instructs documentation if attempting combinations despite the listing.
    • Even with rationale, listed agents are identified as ‘Contraindicated as Concomitant Therapy.’
    Billing Rule

    Include HCPCS J2357 and reference NDC(s) on PA/claims

    For PA and claims, include HCPCS code J2357 (injection, omalizumab, 5 mg) with appropriate units and reference the product NDC when identifying the administered preparation.

    • HCPCS: J2357 — Injection, omalizumab, 5 mg; 1 billable unit = 5 mg.
    • Available NDCs listed: 50242-0214-xx (75 mg), 50242-0215-xx (150 mg syringe), 50242-0040-xx (150 mg vial), 50242-0227-xx (300 mg).
    Documentation Required

    Perform medication reconciliation and document absence of contraindicated agents

    Perform medication reconciliation and document the current medication list to confirm the patient is not concurrently receiving any agent explicitly listed as contraindicated for concomitant therapy with Xolair.

    • The policy requires documentation that the patient is not receiving agents listed as 'Contraindicated as Concomitant Therapy.'
    • Medication reconciliation must be completed prior to initiating or continuing therapy.
    Documentation Required

    Document prescriber attestation that prohibited agents are not being used

    Prescribers must document, in the PA request or medical record, that none of the listed agents are being used concomitantly with omalizumab when requesting or continuing therapy.

    • The policy explicitly states the prescriber must document absence of listed agents when requesting or continuing omalizumab.
    • This documentation is required for PA review and coverage determinations.
    Documentation Required

    Document current medication list and provide rationale if attempting listed combinations

    Document the patient’s current medications and ensure they are not receiving any agents listed as “Agents NOT to be used Concomitantly”; if attempting a combination, provide justification though the policy lists these as contraindicated.

    • The policy instructs providers to document current medications and to provide rationale if attempting combination therapy despite the listing.
    • Absent documentation of exclusion, PA may be denied.
    Documentation Required

    Obtain baseline total IgE and body weight for dose selection

    Obtain pre‑treatment serum total IgE (IU/mL) and measure body weight (kg) to determine the appropriate omalizumab dose and dosing frequency per the policy tables before initiating therapy.

    • Dose determination for many indications is based on serum total IgE measured before starting treatment and body weight; tables specify doses from 75 to 600 mg every 2 or 4 weeks depending on IgE and weight.
    • Some table entries are labeled “Do Not Dose” for very high IgE/weight combinations and must be respected.
    Billing Rule

    Use J2357 (5 mg units) on claims and reference NDCs

    Include the HCPCS code J2357 with the appropriate number of 5‑mg units on claims and may reference the listed NDCs to identify the administered product.

    • J2357 — Injection, omalizumab, 5 mg; 1 billable unit = 5 mg.
    • Reference NDCs for product presentation as listed in the policy.
    Denial Risk

    PA/coverage may be denied if patient is on contraindicated agents

    Requests where the member is prescribed any agent on the policy’s contraindicated concomitant therapy lists may be denied; ensure documentation shows the patient is not receiving those agents.

    • The prior authorization and denial risk language states such requests “may be denied” when a member is prescribed listed agents.
    • Providers should resolve any concurrent prescriptions for listed agents before submission.
    Denial Risk

    Concomitant initiation/use of listed agents may trigger denial

    Initiation or use of any agent named in the document concurrently with Xolair may trigger denial or be considered contraindicated; do not initiate listed therapies while seeking omalizumab coverage.

    • The policy warns that use or initiation of listed agents concomitantly with omalizumab may trigger denial per the 'Agents NOT to be used Concomitantly' section.
    • Requests to continue or initiate concomitant therapy are considered contraindicated.
    Denial Risk

    Requests to co‑administer listed agents may be denied

    Because the policy explicitly lists many agents as ‘Agents NOT to be used Concomitantly,’ requests proposing co‑administration may be denied; do not propose concurrent therapy with any named agent in PA submissions.

    • Repeated, explicit lists of prohibited agents are provided and are grounds for denial if concomitant use is proposed.
    • PA reviewers require confirmation that those agents are not being used.
    Denial Risk

    Concurrent use with named biologic/targeted agents is contraindicated

    Use of any named biologic or targeted agent concomitantly with omalizumab is contraindicated; claims or requests for concurrent therapy with these agents may be denied per the policy.

    • The policy repeatedly identifies numerous biologic, anti‑TNF/anti‑IL, and JAK inhibitors as contraindicated for concomitant use with Xolair.
    • Claims seeking payment for concurrent therapy with these agents may be affected.
    Denial Risk

    High‑weight/IgE combinations labeled “Do Not Dose” may lead to denial

    Respect dosing table entries labeled “Do Not Dose”; very high body weight and IgE combinations flagged as “Do Not Dose” are excluded from dosing recommendations and could lead to denial if billed.

    • The dosing tables include entries indicating “Do Not Dose” for specific high IgE/weight combinations.
    • Coverage requires dosing within the table ranges and avoidance of 'Do Not Dose' combinations.
    Ilaris (canakinumab), Ilumya (tildrakizumab-asmn), Imuldosa (ustekinumab-srlf), Inflectra (infliximab-dyyb), Kevzara (sarilumab)
    Implication for PA reviewersPrior authorization reviewers will require confirmation that none of these agents are concomitantly prescribed
    inv-38: Agents NOT to be used Concomitantly — definition referencing repeated list entries
    Frequent list itemsInfliximab (and biosimilars such as Inflectra), sarilumab (Kevzara), anakinra (Kineret), mepolizumab (Nucala), baricitinib (Olumiant)
    Additional agents listedOpzelura (ruxolitinib), Orencia (abatacept), Otezla and Otezla XR (apremilast), mirikizumab (Omvoh), omalizumab-igec (Omlyclo)
    Policy noteThe document repeatedly restates this list across sections; stated status = 'Agents NOT to be used Concomitantly'
    inv-39: Dose determination — definition describing dose/frequency determination by IgE and body weight
    Dose/frequency determinantsDose (mg) and dosing frequency (every 2 or 4 weeks) are determined by pre-treatment serum total IgE (IU/mL) and body weight (kg)
    Indication dependenceFor certain indications (asthma, chronic rhinosinusitis with nasal polyps, IgE‑mediated food allergy) use IgE+weight tables to select dose
    Non‑IgE dependent indicationChronic spontaneous urticaria dosing (150 or 300 mg every 4 weeks) is not dependent on serum IgE or body weight
    inv-40: Do Not Dose — explanation that table entries labeled 'Do Not Dose' indicate combinations where administration is not recommended
    Meaning of 'Do Not Dose' entriesTable entries labeled 'Do Not Dose' indicate combinations of body weight and IgE for which omalizumab administration is not recommended per the policy
    Coverage implicationDo Not Dose combinations are excluded from dosing recommendations and may lead to denial if billed
    Provider actionIf proposing treatment for combinations listed as 'Do Not Dose', provide clinical justification; expect PA scrutiny